85
Participants
Start Date
October 1, 2023
Primary Completion Date
April 1, 2027
Study Completion Date
April 1, 2029
MRD-guided therapy
MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
Qilu Hospital of Shandong Univertisy, Jinan
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan
Yantai Yuhuangding Hospital, Yantai
The Affiliated Hospital of Qingdao University, Qingdao
Jinan Central Hospital, Jinan
Shandong Provincial Hospital
OTHER_GOV
Jinan Central Hospital
OTHER
Yantai Yuhuangding Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Qilu Hospital of Shandong University
OTHER